Sensei Biotherapeutics

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and delivery of next-generation immunotherapies for the treatment of cancer and infectious diseases. The company has developed a proprietary phage-based platform, ImmunoPhage, which enables the rapid generation of immune activators to fully engage the immune system. Leveraging its proprietary ImmunoPhage platform, Sensei Biotherapeutics is developing a library of ImmunoPhage, called Phortress, targeting multiple tumor-associated antigens.